Market Overview - The Hang Seng Index, the Hang Seng China Enterprises Index, and the Hang Seng Tech Index fell by 1.3%, 1.8%, and 2.5% respectively, with the main board turnover decreasing by 15.8% to HKD 204.3 billion [1] - The decline in technology and healthcare stocks was attributed to delays in Oracle's OpenAI data center projects and lower-than-expected acquisition amounts in the healthcare sector [1] - Conversely, the gold and consumer sectors saw gains, driven by rising international gold prices and positive retail sales data for January to November 2025 [1] Economic Data - National fixed asset investment totaled CNY 4.44 trillion from January to November 2025, down 2.6% year-on-year, with a notable increase in project investment excluding real estate, which grew by 0.8% [3] - Social retail sales reached CNY 4.56 trillion, marking a 4.0% year-on-year increase, with November sales at CNY 438.98 billion, up 1.3% [3] Real Estate Sector - In the real estate market, new home sales in 30 major cities fell by 37.1% year-on-year, with significant declines across all city tiers [4] - New construction area decreased by 27.7% year-on-year, while the sales area of commercial housing dropped by 17.9% [4] - The price index for new residential properties in 70 cities fell by 2.8%, indicating a worsening trend compared to previous months [4] Industry Dynamics - The renewable energy and utility sectors showed mixed performance, with the environmental sector performing well, as companies like China Everbright Environment and Beijing Enterprises Water Group saw stock increases [5] - The automotive sector experienced significant declines, particularly in the autonomous driving and Robotaxi segments, with companies like Cao Cao Travel dropping by 10.7% [5] - The healthcare sector, represented by the Hang Seng Healthcare Index, fell by 3.7%, primarily due to disappointing acquisition terms for a prominent company in the sector [6] Healthcare Sector Insights - The acquisition of Arthrosi by Sobi US was valued at USD 950 million upfront, with additional milestone payments, but fell short of market expectations, leading to a 20% drop in the stock price of the involved company [6] - Despite the recent downturn, there remains optimism for leading innovative pharmaceutical companies in the sector [6]